BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21327451)

  • 1. Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Kawamura K; Imamoto T; Takanami M; Ichikawa T
    Int J Clin Oncol; 2011 Aug; 16(4):366-72. PubMed ID: 21327451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
    Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
    Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
    Jung K; Lein M; Stephan C; Von Hösslin K; Semjonow A; Sinha P; Loening SA; Schnorr D
    Int J Cancer; 2004 Sep; 111(5):783-91. PubMed ID: 15252851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
    Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
    J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer.
    Elfar GA; Ebrahim MA; Elsherbiny NM; Eissa LA
    Oncol Res; 2017 Apr; 25(4):641-650. PubMed ID: 27983911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma.
    Granchi D; Garaventa A; Amato I; Paolucci P; Baldini N
    Int J Cancer; 2006 Jul; 119(1):146-51. PubMed ID: 16450378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer.
    Rachner TD; Kasimir-Bauer S; Göbel A; Erdmann K; Hoffmann O; Browne A; Wimberger P; Rauner M; Hofbauer LC; Kimmig R; Bittner AK
    Clin Cancer Res; 2019 Feb; 25(4):1369-1378. PubMed ID: 30425091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.
    Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA
    Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
    Chen HX; Li HZ; Li HJ; Shi BB; Jin W; Cheng XQ
    Zhonghua Wai Ke Za Zhi; 2007 Mar; 45(6):412-4. PubMed ID: 17537330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease.
    Christoph F; König F; Lebentrau S; Jandrig B; Krause H; Strenziok R; Schostak M
    World J Urol; 2018 Feb; 36(2):187-192. PubMed ID: 29204705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
    Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
    Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy effectively suppresses interleukin-20, receptor activator of nuclear factor kappa-B ligand, and osteoprotegerin levels in patients with lung adenocarcinoma and bone metastasis.
    Yu M; Su Y; Cui D; Sun Q; Luan B; Zhao D
    J Cancer Res Ther; 2016; 12(2):963-8. PubMed ID: 27461682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone metastases detection by circulating biomarkers: OPG and RANK-L.
    Mercatali L; Ibrahim T; Sacanna E; Flamini E; Scarpi E; Calistri D; Ricci M; Serra P; Ricci R; Zoli W; Kang Y; Amadori D
    Int J Oncol; 2011 Jul; 39(1):255-61. PubMed ID: 21491082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
    Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
    Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
    J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.
    Burton DW; Geller J; Yang M; Jiang P; Barken I; Hastings RH; Hoffman RM; Deftos LJ
    Prostate; 2005 Feb; 62(3):275-81. PubMed ID: 15389781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.